普莱柯 (603566.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

11.3x

Market Cap

CNY 3.54B

MomentumView details →

1D Return

−0.68%

YTD Return

−14.72%

RSI (14)

55.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

11.3x

Market Cap

CNY 3.54B

RSI (14)

55.9

MomentumView details →

1D Return

−0.68%

YTD Return

−14.72%

ProfitabilityView details →

Gross Margin

58.74%

Net Margin

16.30%

EBITDA Margin

30.99%

ROE (TTM)

6.53%

ROA (TTM)

5.37%

Asset Turnover

0.33x

GrowthView details →

Revenue YoY

−2.32%

EPS YoY

+45.69%

FCF YoY

−19.03%

Revenue CAGR 3Y

−3.95%

EPS CAGR 3Y

+1.27%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.11

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.00%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

3.82x

Quick Ratio

3.19x

Div Yield

5.66%

Div Rate

CNY 0.60

Div Growth 1Y

−33.33%

Financials snapshotView financials →

Revenue (TTM)

1.06B

Net Income (TTM)

172.82M

Op. CF (TTM)

272.92M

Next earningsOct 22, 2026 →

Latest newsMore news →

Pulike Biological Engineering announced its H1 2026 results with revenue of 491 million yuan, down 12.18% year-on-year, and net profit attributable to shareholders of 77.32 million yuan, down 33.45% year-on-year.11d ago

Pulike's controlled subsidiary Zhongpu Biological Pharmaceutical Co., Ltd. received veterinary drug product approval numbers from the Ministry of Agriculture and Rural Affairs for two foot-and-mouth disease vaccines, enabling production.45d ago

Similar companies

Denali Therapeutics Inc.DNLI 硕世生物688399.SH Veracyte, Inc.VCYT Mirxes Holding Company Limited02629.HK Qyuns Therapeutics Co., Ltd.02509.HK AbCellera Biologics Inc.ABCL Find similar companies →

Latest newsMore news →

Pulike Biological Engineering announced its H1 2026 results with revenue of 491 million yuan, down 12.18% year-on-year, and net profit attributable to shareholders of 77.32 million yuan, down 33.45% year-on-year.11d ago Pulike's controlled subsidiary Zhongpu Biological Pharmaceutical Co., Ltd. received veterinary drug product approval numbers from the Ministry of Agriculture and Rural Affairs for two foot-and-mouth disease vaccines, enabling production.45d ago